DiaMedica Therapeutics to Provide a Business Update and Report Second Quarter 2024 Financial Results August 8, 2024
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company, has announced it will release its second quarter 2024 financial results on August 7th, after market close. The company will host a live conference call on August 8th at 7:00 AM CT to provide a business update and discuss the financial results.
Interested parties can access the call via web or phone. A webcast replay will be available on the company's website for 12 months, and a telephonic replay until August 15, 2024. DiaMedica is focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke and preeclampsia. DM199 is the first pharmaceutically active recombinant form of the KLK1 protein, an established therapeutic modality in Asia for vascular diseases.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), una compagnia biofarmaceutica in fase clinica, ha annunciato che rilascerà i suoi risultati finanziari del secondo trimestre 2024 il 7 agosto, dopo la chiusura del mercato. L'azienda ospiterà una conferenza telefonica in diretta l'8 agosto alle 7:00 AM CT per fornire un aggiornamento aziendale e discutere i risultati finanziari.
Le parti interessate possono accedere alla chiamata tramite web o telefono. Una registrazione della trasmissione sarà disponibile sul sito web dell'azienda per 12 mesi, e una registrazione telefonica fino al 15 agosto 2024. DiaMedica si concentra sullo sviluppo del KLK1 ricombinante (DM199) per il trattamento dell'ictus ischemico acuto e della preeclampsia. DM199 è la prima forma ricombinante attiva farmacologicamente della proteina KLK1, una modalità terapeutica consolidata in Asia per le malattie vascolari.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), una compañía biofarmacéutica en etapa clínica, ha anunciado que publicará sus resultados financieros del segundo trimestre de 2024 el 7 de agosto, después del cierre del mercado. La empresa llevará a cabo una videoconferencia en vivo el 8 de agosto a las 7:00 AM CT para proporcionar una actualización del negocio y discutir los resultados financieros.
Las partes interesadas pueden acceder a la llamada a través de internet o por teléfono. Una repetición de la transmisión estará disponible en el sitio web de la compañía por 12 meses, y una repetición telefónica hasta el 15 de agosto de 2024. DiaMedica está centrada en el desarrollo de KLK1 recombinante (DM199) para el tratamiento de accidente cerebrovascular isquémico agudo y preeclampsia. DM199 es la primera forma recombinante farmacológicamente activa de la proteína KLK1, una modalidad terapéutica establecida en Asia para enfermedades vasculares.
DiaMedica Therapeutics Inc. (纳斯达克: DMAC), 임상 단계의 생명공학 회사가 2024년 2분기 재무 결과를 8월 7일 시장 종료 후 발표한다고 발표했습니다. 회사는 8월 8일 오전 7:00 CT에 실시간 컨퍼런스 콜을 개최하여 사업 업데이트와 재무 결과에 대해 논의할 예정입니다.
관심 있는 분들은 웹이나 전화로 전화를 걸 수 있습니다. 웹캐스트 재생은 회사 웹사이트에서 12개월 동안 제공되며, 전화 재생은 2024년 8월 15일까지 가능합니다. DiaMedica는 재조합 KLK1 (DM199)의 개발에 집중하고 있으며, 이는 급성 허혈성 뇌졸중 및 자간증 치료에 사용됩니다. DM199는 KLK1 단백질의 최초의 약리학적으로 활성화된 재조합 형태로, 아시아에서 혈관 질환을 위한 확립된 치료 방법입니다.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), une entreprise biopharmaceutique en phase clinique, a annoncé qu'elle publiera ses résultats financiers du deuxième trimestre 2024 le 7 août, après la clôture du marché. L'entreprise organisera une conférence téléphonique en direct le 8 août à 7h00 CT pour fournir une mise à jour sur l'activité et discuter des résultats financiers.
Les parties intéressées peuvent accéder à l'appel via Internet ou par téléphone. Un replay du webinaire sera disponible sur le site Web de l'entreprise pendant 12 mois, et un replay téléphonique jusqu'au 15 août 2024. DiaMedica se concentre sur le développement du KLK1 recombinant (DM199) pour le traitement de l'accident vasculaire cérébral ischémique aigu et de la prééclampsie. DM199 est la première forme recombinante pharmaceutiquement active de la protéine KLK1, une modalité thérapeutique établie en Asie pour les maladies vasculaires.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC), ein biopharmazeutisches Unternehmen in klinischen Phasen, hat angekündigt, dass es seine Finanzergebnisse für das zweite Quartal 2024 am 7. August nach Börsenschluss veröffentlichen wird. Das Unternehmen wird am 8. August um 7:00 Uhr CT eine Live-Konferenzschaltung abhalten, um ein Geschäftsupdate zu geben und die Finanzergebnisse zu besprechen.
Interessierte Parteien können die Telefonkonferenz über das Internet oder telefonisch zugreifen. Eine Wiederholung des Webcasts wird 12 Monate lang auf der Website des Unternehmens verfügbar sein und eine telefonische Wiederholung bis zum 15. August 2024. DiaMedica konzentriert sich auf die Entwicklung von rekombinantem KLK1 (DM199) zur Behandlung von akutem ischämischem Schlaganfall und Präeklampsie. DM199 ist die erste pharmazeutisch aktive rekombinante Form des KLK1-Proteins, eine etablierte therapeutische Modalität in Asien für Gefäßerkrankungen.
- DiaMedica is progressing with the development of DM199 for acute ischemic stroke and preeclampsia
- The company is maintaining transparency by hosting a conference call to discuss financial results and provide business updates
- None.
Conference Call details:
Date: |
Thursday, August 8, 2024 |
Time: |
7:00 AM CT / 8:00 AM ET |
Web access: |
|
Dial In: |
(646) 357-8785 |
Conference ID: |
35082 |
Interested parties may access the conference call by dialing in or listening to the simultaneous webcast. Listeners should log on to the website or dial in 15 minutes prior to the call. The webcast will remain available for playback on our website, under investor relations - events and presentations, following the earnings call and for 12 months thereafter. A telephonic replay of the conference call will be available until August 15, 2024, by dialing (888) 660-6345 (US Toll Free) and entering the replay passcode: 35082#.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on acute ischemic stroke and preeclampsia. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240801159643/en/
Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
skellen@diamedica.com
For Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
Source: DiaMedica Therapeutics Inc.
FAQ
When will DiaMedica Therapeutics (DMAC) release its Q2 2024 financial results?
When is DiaMedica's (DMAC) Q2 2024 earnings conference call scheduled?
What is DiaMedica Therapeutics' (DMAC) lead candidate and its target treatment?
What is unique about DiaMedica's (DMAC) DM199 product?
